Global CetirizineHydrochloride Market, by Dosage Form (Tablet, Syrup, and Solution), by AgeGroup (Adult and Pediatric), by Application (Allergic Rhinitis, AllergicConjunctivitis, Eczema, and Others), by Distribution Channel (HospitalPharmacies, Retail Pharmacies, and Retail Pharmacies), and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa) wasvalued at US$ 1,100 million in 2017, and is projected to exhibit a CAGR of 3.2%over the forecast period (2018 – 2026), as highlighted in a new reportpublished by .
Increasing regulatory approvalsfor novel cetirizine formulation to augment the market growth The cetirizinehydrochloride market is expected to gain significant traction over the forecastperiod. This is owing to the pharmaceutical companies operating in the marketthat are focused on developing novel therapies. Such developments extend theapplications of cetirizine hydrochloride for treating eye allergies and oculardiseases. For instance, in May 2017, the FDA approved the ophthalmic solutionnamed Zerviate developed by Aciex Therapeutics, Inc., for topical applicationof the second-generation histamine-1 (H1) receptor antagonist for use intreating ocular itching associated with allergic conjunctivitis. The FDAapproval was based on the New Drug Application providing data that demonstratedthe efficacy, safety, and tolerability of cetirizine ophthalmic solution inphase 3 phase clinical trials using the conjunctival antigen challenge (CAC)model.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2069
Furthermore, in September 2017,Nicox Ophthalmics, Inc., a subsidiary of Nicox S.A. entered into an exclusivelicensing agreement with Eyevance Pharmaceuticals LLC, for thecommercialization of Zerviatetm (cetirizine ophthalmic solution) 0.24%, in theUS, thereby pursuing the expansion of the product into additional markets.
Browse 28 Market Data Tables and22 Figures spread through 148 Pages and in-depth TOC on “CetirizineHydrochloride Market - Global Forecast to 2026, by Dosage Form (Tablet, Syrup,and Solution), by Age Group (Adult and Pediatric), by Application (AllergicRhinitis, Allergic Conjunctivitis, Eczema, and Others), by Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and Retail Pharmacies), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).”
The market players are adoptingstrategies such as mergers and acquisitions to enhance the product portfolio bygaining market access of cetirizine hydrochloride pipeline products and tofurther address major segments of the ophthalmic market, including allergy andinflammation. For instance, in 2014, Nicox S.A. acquired Aciex Therapeutics,Inc., the U.S. based ophthalmic development pharmaceutical company with astrong late stage therapeutic pipeline in ophthalmology, thereby diversifyingthe product portfolio and gaining commercial rights of the product in the U.S.Also, in 2017, the pharmaceutical company Strides Shasun, headquartered inBangalore received approval for allergy drug Cetirizine Hydrochloride in theU.S. Under the agreement, the company will manufacture the product at itsflagship facility at Bangalore. The product is marketed by Strides Pharma Inc.in the US market.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/cetirizine-hydrochloride-market-2069
Key Takeaways of the CetirizineHydrochloride Market:
The global cetirizinehydrochloride market is expected to exhibit a CAGR of 3.2% over the forecastperiod, owing to the launch and approval of products with novel formulationsand increasing incidence of allergic rhinitis
Among dosage form, the tabletsegment holds a dominant position in the cetirizine hydrochloride market, asthey provide a cheaper alternative than the other dosage forms along withhigher shelf-life, better absorption, and dissolution
Among age group, the pediatricsegment holds a dominant position in the cetirizine hydrochloride market, owingto the high rate of disease diagnosis among the pediatric population, as thegroup is highly susceptibility to allergic disease
Among application, the hay feversegment holds a dominant position in the cetirizine hydrochloride market, owingto the high prevalence of the condition in North America, Europe, and AsiaPacific.
Some of the major playersoperating in the global cetirizine hydrochloride market include, Johnson andJohnson, Mylan, Inc., Nicox S.A., Strides Shasun, Apotex, Inc., Teva UKLimited, Aurobindo Pharma Limited, Jubilant Life Sciences, Tris Pharma, Inc.,and Cipla Ltd
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2069
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
